Open Access<p>Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date</p>
Author(s) -
Xiaoming Jia,
Stephanie Koh,
Mahmoud Al Rifai,
Roger S. Blumenthal,
Salim S. Virani
Publication year - 2020
Publication title -
vascular health and risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.892
H-Index - 68
eISSN - 1178-2048
pISSN - 1176-6344
DOI - 10.2147/vhrm.s210149
Subject(s) - medicine , eicosapentaenoic acid , omega 3 fatty acid , fish oil , fatty acid , docosahexaenoic acid , biochemistry , polyunsaturated fatty acid , fish <actinopterygii> , chemistry , fishery , biology
Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.